MedTrace Logo

The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes

NCT02081170 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2014-03-07

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of intravitreal autologous platelet concentrate (APC) injection during the surgery for refractory macular holes.

Conditions

  • Macular Hole With High Myopia (Spherical Equivalent ≤ -6.0 Diopters) or,
  • Large Size Macular Hole (Diameter > 600 Microns) or
  • Recurred or Failed Macular Hole From Previous Surgery
  • or Chronic Macular Hole (Symptom Duration > 6 Months)

Interventions

PROCEDURE

Autologous platelet concentrate

1. pars plana vitrectomy 2. internal limiting membrane removal 3. Fluid-air exchange 4. Intravitreal autologous platelet concentrate injection 5. Intravitreal gas (14% C3F8) injection 6. Keep prone position for 7-14 days after surgery

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02081170 on ClinicalTrials.gov